Fintech PR
Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs
USA News Group News Commentary
Issued on behalf of PlantX Life Inc.
VANCOUVER, BC, Oct. 24, 2024 /PRNewswire/ — USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it’s no wonder why analysts at SNS Insider are projecting the Weight Loss Drugs Market to grow at a whopping 43.73% CAGR through 2032. It’s one of the fastest growing markets in pharmaceuticals, with nearly one in four employers saying they’re either somewhat or very likely to begin covering the cost of anti-obesity medications within the next year. Health and wellness companies are responding in kind, with recent market developments coming from: PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF), Novo Nordisk A/S (NYSE: NVO), Eli Lilly and Company (NYSE: LLY), Viking Therapeutics, Inc. (NASDAQ: VKTX), and Roche Holding AG (OTCQX: RHHBY).
The article continued: According to Morgan Stanley, the global market for blockbuster obesity drugs could increase by more than 15x over the next five years, as their benefits expand beyond weight loss, with expected implications for consumer goods and longevity. With big pharma players entering the race, new weight loss drugs could be developed even faster.
PlantX Life Inc. Announces Joint Venture with LIV3 to Launch SugarShield Supplement Addressing the USD 5.24 Billion Weight Loss Management Supplement Market
PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF), a pioneer in building strong communities and operating innovative experiential online and in-store platforms that make it easier for individuals to lead happier and healthier lives, today announced a joint venture with LIV3, founded by Christopher Mearns, to launch their SugarShield supplement. Aimed at addressing the growing US$5.24 billion Weight Loss Management Supplement Market, PlantX will manage the design of SugarShield’s branding and packaging as part of the JV, while also developing a user-friendly e-commerce platform to support the supplement’s launch. PlantX Life will lead all marketing intitiatives, including utilizing its proprietary SEO strategies to build the brand’s presence, while Chris Mearns will oversee the product supply. Net profits from all sales will be shared equally, with a 50/50 split.
“As the weight loss supplement market continues to expand, driven by excitement around the popularity in products once designed for treating effects of type 2 diabetes, we at PlantX see this as an opportunity to offer a plant-based alternative without the synthetic properties,” said Lorne Rapkin, CEO of PlantX. “We believe Chris Mearns has developed what can be considered ‘nature’s Ozempic’ with SugarShield. We’re confident that the branding, packaging, and website we create will reflect the innovation and benefits of this product, making it stand out in the growing weight management market.”
The joint venture with PlantX will provide LIV3 with the resources to create a strong online presence for SugarShield. PlantX’s expertise in branding and digital platforms will help the supplement reach health-conscious consumers worldwide.
LIV3 suggests that SugarShield is designed to help users boost energy, curb cravings, and simplify weight management—all without the need for restrictive diets. After years of development, Christoper Mearns has created a formula that provides consumers with the health benefits typically associated with sugar-free diets, while fitting seamlessly into everyday lifestyles. According to Mearns, the supplement works by reducing uric acid, a key contributor to cellular stress, enabling users to improve their metabolic health.
“With LIV3’s SugarShield, consumers can detox from the negative effects of fructose without changing their diet,” said Christopher Mearns, founder of LIV3. “This supplement improves energy levels through enhanced mitochondrial function, supports glucose utilization, and increases insulin sensitivity, leading to weight loss and improved metabolic conditions. We’ve already begun designing the branding and packaging with the PlantX team, and we’re very excited about the upcoming launch. Simply put, our metabolic health was broken by daily fructose intake, and luteolin is the answer because it blocks the harmful effects of fructose.”
An integral part of this collaboration is Paul Gross, a long-time member of PlantX’s medical panel. Dr. Gross has played a crucial role in validating the medical science behind SugarShield, ensuring that the supplement’s formulation is both effective and grounded in scientific research. His expertise and support have been instrumental in building confidence in the potential benefits of SugarShield, allowing both PlantX and LIV3 to bring this innovative product to market with the assurance of its efficacy.
This joint venture aligns with PlantX’s ongoing commitment to expanding its plant-forward wellness offerings while tapping into the rapidly growing health and supplement sectors.
CONTINUED… Read this and more news for PlantX Life at: https://usanewsgroup.com/2024/10/08/from-plants-to-plates-wellness-delivered/
In other industry developments and happenings in the market this week include:
Novo Nordisk A/S (NYSE: NVO), the company behind Ozempic, recently announced that its oral semaglutide (Rybelsus®) (the active ingredient in Ozempic and Wegovy) reduced the risk of major adverse cardiovascular events by 14% in adults with type 2 diabetes, according to the SOUL trial. The randomized, double-blinded study enrolled 9,650 participants with type 2 diabetes and cardiovascular or chronic kidney disease, with 49% also receiving SGLT2 inhibitors during the trial.
“We are pleased to see that the results from SOUL demonstrate that oral semaglutide reduces the risk of cardiovascular events and that the benefits of oral semaglutide come on top of standard of care,” said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “Approximately one in three adults with type 2 diabetes also have cardiovascular disease; therefore, it is crucial to have therapies that can address both conditions.”
The trial met its primary objective by showing a 14% reduction in MACE for those treated with oral semaglutide compared to placebo. The primary endpoint, defined as the first occurrence of cardiovascular death, non-fatal heart attack, or non-fatal stroke, saw contributions from all three components, confirming oral semaglutide’s superior MACE reduction.
Eli Lilly and Company (NYSE: LLY), maker of Ozempic and Wegovy competitor drugs Mounjaro and Zepbound, recently said it had sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets. The new lawsuits against Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine of Nevada are the first to target copycat tirzepatide since the U.S. Food and Drug Administration (FDA) removed the drug from its short supply list earlier this month.
“Lilly is bringing these actions to protect American consumers from direct patient safety risks,” said a Lilly spokesperson, adding that the defendants were making false claims regarding efficacy and safety, while also misleading consumers about the clinical data supporting those claims.
Earlier this year, Eli Lilly already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, which is also approved to treat type 2 diabetes under the brand name Mounjaro. Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages.
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced back in June that it had presented preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association. The presentation highlighted the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide.
“The amylin receptor plays an important role in food intake and metabolic control, making it an attractive target for therapeutic intervention in obesity,” said Brian Lian, Ph.D., CEO of Viking. “These data demonstrate the potent activity of a series of novel, internally developed, amylin and calcitonin dual agonists and represent an exciting expansion of our pipeline in obesity and metabolic diseases. This program provides Viking with additional opportunities to develop novel, differentiated therapies for obesity with potentially best-in-class profiles.”
Roche Holding AG (OTCQX: RHHBY), a Swiss-based global pharmaceutical leader, recently told investors that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than US$3.6 billion in annual sales. According to a presentation Roche gave, the revenue projection applies on aggregate to weekly injection CT-388—which is similar to Lilly’s Zepbound—and daily pill CT-996 as well as CT-868 against type 1 diabetes. In total, at least seven drugs in Roche’s development pipeline have peak sales potential of more than US$3.6 billion.
According to a report from Financial Times, Roche is planning to launch 20 medicines by the end of the decade, while cutting research costs for new drugs by a fifth.
“We want to make sure our engine works extremely efficiently,” said Thomas Schinecker, CEO of Roche, in the presentation that outlined a focus on oncology, haematology, neurology, cardiovascular and metabolic diseases, eye diseases and immune diseases. “The bar is high.”
Source: https://usanewsgroup.com/2024/10/08/from-plants-to-plates-wellness-delivered/
CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for PlantX Life Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of PlantX Life Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of PlantX Life Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of PlantX Life Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of PlantX Life Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
View original content:https://www.prnewswire.co.uk/news-releases/health-and-wellness-industry-embraces-surge-in-demand-for-weight-loss-drugs-302286062.html
- Piloted by 60 enterprise businesses including: Patagonia, On, Indeed, NordSecurity and Fubo
- AI helps businesses increase payment conversion rates by up to 6% compared to legacy implementations
NEW YORK, Jan. 9, 2025 /PRNewswire/ — Adyen, the global financial technology platform of choice for leading businesses, announces the launch of Adyen Uplift. The AI-powered payment optimization suite will help businesses increase payment conversion, simplify fraud management, and reduce the cost of payments. Adyen’s customers can utilize data-driven, tailored performance recommendations and opportunities to test different payment configurations to maximize performance.
Saving businesses from trading off between conversion, risk, and cost
The complexity of payment management still holds businesses back from reaching their ambitions. They constantly need to compromise between conversion, fraud, and cost. Thanks to Adyen Uplift, businesses can optimize the full payments funnel with AI. AI-powered payment optimizations bundled in a single product suite are trained on Adyen’s global transaction dataset. Rather than navigating the complexity of payments in operational silos, the AI-first approach uses risk-based intelligence and automated conversion optimization to help businesses get more out of payments. The pilot has shown a significant effect on profits, with businesses seeing an overall uplift of up to 6% on their payment conversion rate.
“Balancing risk management, driving conversion, and minimizing cost has always required ineffective compromises – until now” said Carlo Bruno, VP of Product at Adyen. “Adyen Uplift changes the game by unleashing the depth and power of AI to solve for real-time payment optimization. This will transform cost savings and performance, redefining business efficiency in 2025 and beyond.”
$1 trillion+ payments data
Businesses and other providers rely on limited datasets, impacting their ability to recognize shoppers and payment behavior. With Adyen Uplift, companies benefit from AI trained on over a trillion dollars worth of global payments data from Adyen’s single platform.
“We’ve increased our conversion rate by up to 2% with Adyen’s AI, making a real difference to both our performance and cost efficiency, while keeping fraud under control,” commented Luca Spichtig, Head of Digital Operations & Projects at On.
Adyen has processed payments for over one billion consumers globally, giving its AI solutions a strong basis to differentiate good shoppers from fraudsters. When an Adyen customer encounters a new shopper, there is a high likelihood that Adyen has seen the shopper elsewhere on the platform. For a retail merchant on the Adyen platform, there is more than a 90% chance that Adyen has seen that shopper before. When a good shopper is identified, AI optimizations allow them to speed through checkout whilst shoppers and retailers also benefit from precise payment fraud mitigation.
“We’ve increased our conversion rate on customer initiated transactions by 10% by leveraging Adyen’s AI technology, which optimizes the entire payment funnel while maintaining control over fraud and costs,” commented Kes Saulis, Head of Payments at Nord Security.
The AI-first approach to fighting fraud
Today, the fraud control process is highly complex, requiring businesses to implement extensive manual rules to combat ever-evolving fraud techniques. With Adyen Uplift, businesses can automate fraud control by removing the operational burden from fraud management teams. The solution automates and refines risk management without relying on manual rules. This enables businesses to lower fraud levels and reduce false positives, depending on their risk appetite.
Businesses piloting the risk product have seen the impact firsthand. Adyen’s pilot enterprise customers have reduced their manual risk rules by 86% on average, and 35% of customers have completely eliminated manual rules saving valuable time and resources.
Adyen’s customer Indeed, a leading job matching and hiring platform, was able to run AI-based optimization experiments that are tailored to the unique characteristics of its business. This translated into a reduction in operational workload by automating processes to drive efficiency.
Reduce payment processing costs by up to 5%
Today, businesses are more focused than ever on their bottom line, yet many still view payments as a commodity rather than a powerful cost-saving strategy.
Adyen Uplift has reduced payment cost by up to 5% for pilot customers in the U.S. Adyen’s AI selects the best routes with the best rates for transactions to help minimize total cost of payment. Pilot customers also experienced cost savings through Adyen’s optimizations, which tailored the shopper-facing checkout flow to their needs.
To learn more about Adyen Uplift, click here.
About Adyen
Adyen (ADYEN:AMS) is the financial technology platform of choice for leading companies. By providing end-to-end payments capabilities, data-driven insights, and financial products in a single global solution, Adyen helps businesses achieve their ambitions faster. With offices around the world, Adyen works with the likes of Meta, Uber, H&M, eBay, and Microsoft. Adyen continuously improves and expands its product offering as part of its ordinary course of business. New products and features are announced via press releases and product updates on the company’s website.
Logo – https://mma.prnewswire.com/media/1490851/Logo__Adyen_green_RGB_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/introducing-adyen-uplift-the-payment-solution-optimizing-every-transaction-with-ai-302347156.html
New logo reflects ability to power mission-critical decisions with confidence
LONDON, Jan. 9, 2025 /PRNewswire/ — Crisil Limited, a provider of ratings, data, research, analytics and solutions, today unveils its new brand logo.
The new brand identity, ‘Crisil’ (earlier written as CRISIL), reinforces the company’s position as a global, insights-driven analytics firm, building on a distinguished legacy of close to four decades.
Large and highly respected firms partner with us for the most reliable opinions on risk in India, and for uncovering powerful insights and turning risks into opportunities globally. We are integral to multiplying their opportunities and success.
Says Amish Mehta, Managing Director & CEO, Crisil, “Our reimagined brand expresses a more progressive vision of our future. It celebrates a pioneering and illustrious past and showcases our commitment to deliver actionable insights to clients. Our people’s analytical rigour and domain expertise will continue to set standards and empower clients to make mission-critical decisions with confidence. The new brand identity guides us in shaping how we present ourselves to the world, influencing every interaction internally and externally to help us deliver exceptional client value.”
The strategic brand transformation positions Crisil’s businesses — Crisil Ratings, Crisil Intelligence (formerly MI&A), Crisil Coalition Greenwich, and Crisil Integral IQ (formerly GR&RS) — under a cohesive identity that offers a consistent and more connected experience for clients around the world.
Crisil Ratings: Offers independent credit ratings in India that empower informed decisions and objective benchmarking by lenders, investors and issuers.
Crisil Intelligence: Offers insights, consulting, technology-driven risk solutions and advanced data analytics, serving clients across government, private and public enterprises, empowering them to make informed decisions.
Crisil Coalition Greenwich: Offers strategic benchmarking, analytics and insights to the financial services industry and specialises in providing unique, high-value and actionable information to help clients measure and drive their business performance.
Crisil Integral IQ: Offers solutions and actionable intelligence to financial institutions around the globe to deliver strategic transformation, optimise risk and drive operational excellence.
The main logo in bold black is simple yet strong, symbolising excellence and the certainty that we deliver. Complementing this, our business logos now feature a distinct teal colour that conveys the confidence and trust rooted in rigour and domain expertise.
About Crisil Limited
Crisil is a global, insights-driven analytics company. Our extraordinary domain expertise and analytical rigour help clients make mission-critical decisions with confidence.
Large and highly respected firms partner with us for the most reliable opinions on risk in India, and for uncovering powerful insights and turning risks into opportunities globally. We are integral to multiplying their opportunities and success.
Headquartered in India, Crisil is majority owned by S&P Global.
Founded in 1987 as India’s first credit rating agency, our expertise today extends across businesses: Crisil Ratings, Crisil Intelligence, Crisil Coalition Greenwich and Crisil Integral IQ.
Our globally diverse workforce operates in the Americas, Asia-Pacific, Europe, Australia and the Middle East, setting the standards by which industries are measured.
For more information, visit www.Crisil.com
Connect with us: LINKEDIN | TWITTER | YOUTUBE | FACEBOOK
Disclaimer
This press release is transmitted to you for the sole purpose of dissemination through your newspaper/ magazine/ agency. The press release may be used by you in full or in part without changing the meaning or context thereof but with due credit to Crisil. However, Crisil alone has the sole right of distribution of its press releases for consideration or otherwise through any media including websites, portals, etc.
Crisil has taken due care and caution in preparing this press release. Information has been obtained by Crisil from sources which it considers reliable. However, Crisil does not guarantee the accuracy, adequacy or completeness of information on which this press release is based and is not responsible for any errors or omissions or for the results obtained from the use of this press release. Crisil especially states that it has no financial liability whatsoever to the subscribers/ users/ transmitters/ distributors of this press release.
Logo: https://mma.prnewswire.com/media/2594759/Crisil_Limited_New_Logo.jpg
Photo 1: https://mma.prnewswire.com/media/2594763/Crisil_Ratings_Logo.jpg
Photo 2: https://mma.prnewswire.com/media/2594762/Crisil_Intelligence_Logo.jpg
Photo 3: https://mma.prnewswire.com/media/2594760/Crisil_Coalition_Greenwich_Logo.jpg
Photo 4: https://mma.prnewswire.com/media/2594761/Crisil_Integral_IQ_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/crisil-unveils-a-new-brand-identity-302347103.html
DUBAI, UAE, Jan. 9, 2025 /PRNewswire/ — MANTRA, a purpose-built layer 1 blockchain for tokenized real-world assets (RWAs) has signed a US$1 billion agreement with DAMAC Group, a prominent investment conglomerate, renowned for its diversified portfolio that spans across key sectors such as real estate development, hospitality, data centres, and more, to tokenize assets in the Middle East.
The collaboration between MANTRA and the DAMAC Group will enable token-based financing for a diverse range of assets within the group’s extensive portfolio of companies, with a minimum value of US$1 billion.
The DAMAC Group assets will be available in early 2025, exclusively on MANTRA Chain, marking a bold step in leveraging blockchain technology to bring greater transparency, security, and accessibility to DAMAC Group’s wide-ranging assets. This milestone partnership is yet another step in MANTRA’s vision to become the preferred ledger of record for real-world assets.
“This partnership with DAMAC Group is an endorsement for the RWA industry. We’re thrilled to partner with such a prestigious group of leaders that share our ambitions and see the incredible opportunities of bringing traditional financing opportunities onchain,” said John Patrick Mullin, CEO of MANTRA.
Amira Sajwani, Managing Director of Sales & Development at DAMAC, said, “DAMAC is always exploring new technologies to enhance our product offerings. Partnering with MANTRA is a natural extension of our commitment to innovation and forward-thinking solutions. Tokenizing our assets will provide investors with a secure, transparent, and convenient way to access a wide range of investment opportunities.”
The MANTRA and DAMAC Group partnership follows the recent announcement of MANTRA Chain’s Mainnet launch, which went live in October, representing a significant milestone in the integration of traditional finance with blockchain technology.
About MANTRA:
MANTRA is a purpose-built Layer 1 blockchain for real-world assets, capable of adherence to real world regulatory requirements. As a permissionless chain, MANTRA empowers developers and institutions to seamlessly participate in the evolving RWA tokenization space by offering advanced tech modules, compliance mechanisms, and cross-chain interoperability.
Website | Twitter | LinkedIn | Discord
About DAMAC Group:
The DAMAC Group is the multi-billion-dollar business conglomerate of UAE based Hussain Sajwani. The Group’s investments are divided into seven core areas; real estate, capital markets, hotels & resorts, manufacturing, catering, high-end fashion and data centres.
Some of the Group’s most notable activities include DAMAC Properties, one of the region’s largest property developers, the acquisition of the Italian fashion house, Roberto Cavalli and luxury Swiss jewellery brand de GRISOGONO, the 50-storey development DAMAC Towers Nine Elms in London and a luxury resort in the Maldives.
In a bid to disrupt the global data centre landscape, the Group recently announced plans to build data centres through its digital infrastructure company, EDGNEX Data Centers by DAMAC, across different global locations.
Today, the Group’s global footprint extends across North America, Europe, Asia, Middle East and Africa. With its vision firmly set on growth and expansion, the Group continues in its quest for diversification and business excellence.
Visit us at www.damacgroup.com
View original content:https://www.prnewswire.co.uk/news-releases/mantra-and-damac-group-revolutionize-tokenized-real-world-assets-with-us1-billion-deal-302346789.html
-
Fintech PR6 days agoBybit x Block Scholes Report: BTC Options Steady with Call-Put Parity, ETH Braces for Short-Term Volatility
-
Fintech PR6 days agoArtificial Intelligence (AI) in Trading Market to Reach USD 35 Billion by 2030, Growing at a 10% CAGR | Valuates Reports
-
Fintech PR7 days agoDataLend: 2024 Securities Lending Revenue Down 10% YoY to $9.64 Billion
-
Fintech PR6 days agoYear-opening Triumph: Arctech Lands a 1.5GW Solar Project Order in the UAE
-
Fintech2 days agoAsian Financial Forum held next week as the region’s first major international financial assembly of 2025
-
Fintech PR2 days agoOWIT Global Provides Alternative Delivery Models that Adapt to the Continuously Evolving Data Security Demands of the Industry
-
Fintech PR3 days agoHyundai Motor Group Executive Chair Euisun Chung Outlines 2025 Vision Driven by Commitment to Innovation, Overcoming Challenges, and Creating Opportunities in New Year’s Message
-
Fintech PR3 days agoZoomlion Accelerates Global Expansion with Localized Innovations in Saudi Arabia